Sovaldi Sells Big in First Year

According to a Wall Street Journal report, Sovaldi, a newly approved drug to treat Hepatitis C, could see between $5 billion and $9 billion in sales during its first year on the market, one of the largest sales for a new drug's first year.

Read the full report on Becker's Hospital Review.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers